2019-nCoV Outbreak and Cardiovascular Diseases

Cardiovascular Death; Major Adverse Cardiovascular Events Clinical Trial

Official title:

Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04255940
• Other study ID #: 2019nCoV-CVD
• Status: Recruiting
• Start date: January 20, 2020
• Est. completion date: April 30, 2020

Study information

• Verified date: February 2020
• Source: Qilu Hospital of Shandong University
• Contact: Panpan Hao, MD
• Phone: 86-18560086593
• Email: panda.how[@]sdu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.

Description:

This survey aims to assess whether the public anxiety from a novel coronavirus (2019-nCoV) outbreak increases cardiovascular disease risk in China. Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12000
• Est. completion date: April 30, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients visiting emergency department.

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Cardiovascular Death; Major Adverse Cardiovascular Events
• Cardiovascular Diseases

Locations

Country	Name	City	State
China	Affiliated Hospital of Binzhou Medical Universty	Binzhou	Shandong
China	Heze Municipal Hospital	Heze	Shandong
China	First Hospital Affiliated with Shandong First Medical University	Jinan	Shandong
China	Jinan Central Hospital, Shandong University	Jinan	Shandong
China	Shandong Provincial Hospital, Shandong University	Jinan	Shandong
China	Shandong University Qilu Hospital	Jinan	Shandong
China	The Second Hospital of Shandong University	Jinan	Shandong
China	Jining Hospital of Traditional Chinese Medicine	Jining	Shandong
China	Qihe People's Hospital	Qihe	Shandong
China	Affiliated Hospital of Qingdao University Medical College	Qingdao	Shandong
China	Weihai Municipal Hospital	Weihai	Shandong
China	Central Hospital of Zibo	Zibo	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cardiovascular Death		3 months
Secondary	Major Adverse Cardiovascular Events		3 months
Secondary	Times From symptom onset to hospital arrival		3 months
Secondary	Anxiety		3 months